AXSM
Axsome Therapeutics, Inc.Company Information
- Company Name
- Axsome Therapeutics, Inc.
- CIK
- CIK0001579428
- Category
- Large accelerated filer
- Ticker: Exchange
- AXSM: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- AXSM
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-09-08
- Last sale
- 2026-09-03
- Shares purchased (TTM)
- 1,575
- Shares sold (TTM)
- 472,357
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 37,347,468
- Shares outstanding
- 51,799,708
- Ownership
- 72.10%
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- -6.43%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 320 | 305 | 323 | 325 | 303 | 301 | 315 | 327 | 316 | 331 | 386 | 417 | ||||||
| Accounts Receivable Net Current | 277 | 251 | 224 | 197 | 199 | 161 | 142 | 124 | 120 | 101 | 95 | 78 | ||||||
| Inventory Net | 38 | 32 | 28 | 24 | 18 | 16 | 16 | 14 | 15 | 16 | 15 | 10 | ||||||
| Prepaid Expense And Other Assets Current | 21 | 24 | 14 | 20 | 16 | 16 | 12 | 13 | 12 | 12 | 8 | 7 | ||||||
| Assets Current | 657 | 611 | 589 | 565 | 537 | 495 | 485 | 479 | 463 | 460 | 504 | 512 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 19 | 20 | 21 | 22 | 22 | 23 | 5 | 6 | 6 | 6 | 7 | 7 | ||||||
| Goodwill | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | ||||||
| Intangible Assets Net Excluding Goodwill | 37 | 39 | 41 | 42 | 44 | 45 | 47 | 49 | 50 | 52 | 53 | 55 | ||||||
| Other Inventory Noncurrent | - | 31 | 27 | 27 | 24 | 21 | 19 | 15 | 16 | 14 | 11 | 14 | ||||||
| Assets | 761 | 714 | 690 | 669 | 640 | 597 | 568 | 561 | 548 | 546 | 588 | 601 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 79 | 107 | 66 | 54 | 92 | 86 | 72 | 64 | 61 | 54 | 41 | 29 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | 300 | 251 | 233 | 226 | 171 | 149 | 148 | 122 | 117 | 83 | 91 | 78 | ||||||
| Operating Lease Liability Current | 1 | 1 | 0 | 1 | 0 | 0 | 2 | 2 | 1 | 1 | 1 | 0 | ||||||
| Business Combination Contingent Consideration Liability Current | 11 | 11 | 10 | 10 | 9 | 9 | 8 | 8 | 7 | 6 | 6 | 7 | ||||||
| Long Term Debt Current | 70 | 70 | 70 | 70 | 70 | - | 0 | - | - | - | - | - | ||||||
| Liabilities Current | 460 | 439 | 379 | 360 | 342 | 244 | 230 | 196 | 187 | 144 | 139 | 115 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | 69 | 74 | 78 | 90 | 80 | 91 | 92 | 83 | 70 | 70 | 73 | 32 | ||||||
| Long Term Debt Noncurrent | 118 | 118 | 118 | 118 | 118 | 181 | 181 | 180 | 179 | 179 | 178 | 177 | ||||||
| Operating Lease Liability Noncurrent | 22 | 22 | 23 | 23 | 24 | 24 | 6 | 6 | 7 | 7 | 7 | 8 | ||||||
| Finance Lease Liability Noncurrent | 9 | 6 | 4 | 5 | 4 | 4 | 3 | 3 | 3 | 2 | - | - | ||||||
| Liabilities | 678 | 659 | 602 | 596 | 567 | 543 | 511 | 469 | 445 | 402 | 397 | 331 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,505 | 1,425 | 1,394 | 1,351 | 1,303 | 1,235 | 1,180 | 1,141 | 1,086 | 1,048 | 1,027 | 1,006 | ||||||
| Retained Earnings Accumulated Deficit | -1,422 | -1,371 | -1,306 | -1,277 | -1,230 | -1,182 | -1,123 | -1,048 | -983 | -904 | -836 | -737 | ||||||
| Stockholders Equity | 83 | 55 | 88 | 74 | 73 | 53 | 57 | 93 | 103 | 144 | 191 | 270 | ||||||
| Liabilities And Stockholders Equity | 761 | 714 | 690 | 669 | 640 | 597 | 568 | 561 | 548 | 546 | 588 | 601 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 52 | 51 | 51 | 50 | 50 | 49 | 49 | 48 | 48 | 47 | 47 | 47 | ||||||
| Shares Outstanding | 52 | 51 | 51 | 50 | 50 | 49 | 49 | 48 | 48 | 47 | 47 | 47 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAxsome Therapeutics, Inc. (AXSM) — SEC Financial Statements & Analysis
Axsome Therapeutics, Inc. (AXSM) is a pharmaceutical preparations company, incorporated in DE. Axsome Therapeutics, Inc. trades on Nasdaq as: AXSM. Axsome Therapeutics, Inc. (AXSM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, Axsome Therapeutics, Inc. carries a market cap of $12.68B, a P/E ratio of -66.16x, a P/B ratio of 152.20x, a P/S ratio of 16.33x, an enterprise value of $12.55B, and an EV/EBITDA multiple of -67.61x. On profitability, it posts a gross margin of 93.24%, an operating margin of -23.96%, a net margin of -24.68%, a Return on Equity (ROE) of -245.10%, a Return on Assets (ROA) of -27.35%, and a Return on Invested Capital (ROIC) of -650.23%. Per share, it reports EPS of $-3.70, diluted EPS of $-3.70, free cash flow per share of $-1.39, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 56.87% year-over-year, net income growth of -22.38% year-over-year, and EPS growth of -25.91% year-over-year. On the balance sheet, it maintains a current ratio of 1.43x, a quick ratio of 1.30x, working capital of $196.12M, a debt-to-equity ratio of 8.14x, a debt ratio of 0.89, free cash flow of $-71.96M (TTM), and net debt of $-131.89M. Figures sourced from SEC EDGAR.
- Market Cap
- $12.68B
- P/E TTM
- -66.16x
- EPS TTM
- $-3.70
- P/B TTM
- 152.20x
- ROE TTM
- -245.10%
- ROA TTM
- -27.35%
- Debt To Equity
- 8.14x
- Free Cash Flow TTM
- $-71.96M
- Net Revenue TTM Growth 1Y
- 56.87%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Axsome Therapeutics, Inc. in?
Axsome Therapeutics, Inc. (AXSM) operates in the Pharmaceutical Preparations industry.
What exchange does AXSM trade on?
Axsome Therapeutics, Inc. (AXSM) trades on the Nasdaq.
Where is Axsome Therapeutics, Inc. incorporated?
Axsome Therapeutics, Inc. is incorporated in DE.
When was Axsome Therapeutics, Inc. (AXSM)'s most recent SEC filing?
Axsome Therapeutics, Inc. (AXSM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is AXSM's market cap?
Axsome Therapeutics, Inc. (AXSM) has a market capitalization of $12.68B as of 2026-06-30.
What is AXSM's EPS (earnings per share)?
Axsome Therapeutics, Inc. (AXSM)'s trailing twelve month EPS is $-3.70 as of 2026-06-30.
What is AXSM's ROE (return on equity)?
Axsome Therapeutics, Inc. (AXSM)'s trailing twelve month Return on Equity (ROE) is -245.10% as of 2026-06-30.
What is AXSM's ROA (return on assets)?
Axsome Therapeutics, Inc. (AXSM)'s trailing twelve month Return on Assets (ROA) is -27.35% as of 2026-06-30.
What is AXSM's ROIC (return on invested capital)?
Axsome Therapeutics, Inc. (AXSM)'s trailing twelve month Return on Invested Capital (ROIC) is -650.23% as of 2023-09-30.
What is AXSM's EV/EBITDA?
Axsome Therapeutics, Inc. (AXSM)'s trailing twelve month EV/EBITDA is -67.61x as of 2026-06-30.